Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06461910RecruitingPhase 2
Immunotherapy, thymalfasin, and chemo before surgery for stomach cancer
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT05578053Recruiting
Dalpiciclib for hormone receptor–positive advanced breast cancer
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
Shijiazhuang, HebeiAges 18 years+ - NCT05357651RecruitingPhase 1
LB1410 study for advanced lung, colon, and other cancers
This Phase 1 trial tests LB1410, a new cancer treatment, to see if it is safe and may work for people with advanced cancers. It focuses on specific cancer types and requires certain prior treatments and lab test results.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06452316RecruitingPhase 1
Eye drop study for limbal stem cell deficiency
This study tests a new eye drop called CSB-001 for people with limbal stem cell deficiency (LSCD), a condition that damages the cornea. The goal is to see if the drops can help improve the health of the cornea and reduce inflammation.
Loma Linda, CaliforniaAges 18 years+ - NCT06451757RecruitingPhase 3
Sonlicromanol for chronic fatigue in primary mitochondrial disease
This trial tests a new medicine, sonlicromanol, to see if it can ease chronic fatigue and improve muscle function in people with a specific genetic condition called primary mitochondrial disease. If effective, it could offer a new treatment option to improve daily energy and quality of life.
Boston, MassachusettsAges 18 years+ - NCT06455449RecruitingPhase 3
Injectable anifrolumab for polymyositis or dermatomyositis
This study tests a new injectable medicine (anifrolumab) added to your usual treatments for polymyositis or dermatomyositis. It may help reduce disease activity if you have moderate to severe symptoms and are already on stable therapy.
Phoenix, ArizonaAges 18–75 - NCT06456593RecruitingPhase 2
Obefazimod for moderate to severe Crohn's disease
This trial tests an experimental oral medication called obefazimod for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments have not worked well.
Fairhope, AlabamaAges 18–75 - NCT06451718Recruiting
A new implant for keratoconus to avoid corneal transplant
This trial tests a small metal implant placed in the cornea to treat keratoconus, a condition where the cornea thins and bulges. The goal is to see if the implant can safely improve vision and prevent the need for a corneal transplant.
Roma, RomaAges 18 years+ - NCT03127267RecruitingPhase 3
Test of masitinib versus placebo for ALS
This Phase 3 study tests whether masitinib works better than an inactive pill (placebo) to slow ALS progression and keep it safe. It is meant for people recently diagnosed with ALS who meet specific breathing and function score requirements.
Birmingham, AlabamaAges 18–81 - NCT04319848RecruitingPhase 1
Tissue-engineered cornea transplant for specific eye swelling conditions
This Phase 1 trial tests a new, lab-made tissue transplant to improve corneal clarity in people with certain types of corneal endothelium failure (eye swelling) caused by specific conditions. The main goal is to check safety and see if vision and corneal health improve.
SingaporeAges 21–80 - NCT06440759Recruiting
Filter Comparison for Septic Shock with Kidney Failure
This study compares two types of filters used during continuous kidney replacement therapy in patients with septic shock and severe acute kidney injury. The goal is to see which filter works better and is safer.
Kubang Kerian, KelantanAges 18 years+ - NCT06314919Recruiting
Study of a combination pill for high cholesterol
This study tests a single pill that combines two cholesterol-lowering medicines (pitavastatin and ezetimibe). It may be a good fit if you already take a statin or a statin plus ezetimibe and your doctor wants to adjust your treatment.
SeoulAges 19 years+ - NCT05970237Recruiting
Dapagliflozin for type 2 diabetes with high blood pressure
This trial studies whether dapagliflozin (the medicine in Trudapa tabs) is safe and works in people who have both type 2 diabetes and high blood pressure. It may help control blood sugar and blood pressure, while researchers closely watch for side effects.
Incheon, Namdong-guAges 19 years+ - NCT06082102RecruitingPhase 3
Comparing orelabrutinib and lenalidomide with rituximab for MZL
This study tests two different drug combinations for people with marginal zone lymphoma that has come back or stopped responding to previous treatment. One group gets orelabrutinib plus rituximab, and the other gets lenalidomide plus rituximab, to see which works better and has fewer side effects.
Bengbu, AuhuiAges 18 years+ - NCT06371040RecruitingPhase 1
CAR-T cell therapy for severe myasthenia gravis
This trial is testing a new type of cell therapy called CAR-T that targets two proteins (CD19 and BCMA) on certain immune cells. It aims to help people with severe myasthenia gravis that has not improved with standard treatments.
Xi'an, ShaanxiAges 18–80 - NCT06423170RecruitingPhase 2
Camrelizumab plus chemo for unresectable gallbladder cancer
This trial tests a combination of the immunotherapy drug camrelizumab with two chemotherapy drugs (gemcitabine and oxaliplatin, known as GEMOX) for people with gallbladder cancer that cannot be surgically removed. It aims to see if this treatment can help shrink the tumor and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06436534Recruiting
Ganciclovir for stubborn allergic rhinitis
This study tests whether an antiviral medicine called ganciclovir (in capsule form) can help people with stubborn moderate-to-severe allergic rhinitis that doesn't improve with standard treatments. If you have year-round allergies to dust mites and your symptoms are still bothersome, this trial may be an option for you.
Wuhan, HubeiAges 18–65 - NCT06427226RecruitingPhase 2
Testing dapagliflozin to protect the heart during breast cancer chemo
This trial tests whether a daily pill called dapagliflozin can help protect the heart from damage caused by doxorubicin chemotherapy in people being treated for early-stage breast cancer. If you are starting doxorubicin and have a healthy heart, this might lower your risk of heart problems later.
Alexandria, Bab SharqiAges 18–65 - NCT06431685RecruitingPhase 1
Brain radiation, immunotherapy, and chemo for lung cancer spread
This trial tests a combination of low-dose radiation to the whole brain, immunotherapy, and chemotherapy given through a lumbar puncture. It is for people with lung cancer that has spread to the lining of the brain and has not responded to standard treatments.
Chengdu, SichuanAges 18–75 - NCT06430801RecruitingPhase 3
Study of tulisokibart for moderate to severe Crohn's disease
This trial tests a new medicine called tulisokibart for people with moderate to severe Crohn's disease. The medicine may help reduce inflammation and improve symptoms. It is for those who have not had success with other treatments.
Dothan, AlabamaAges 16–80 - NCT06425341RecruitingPhase 2
Test injection to keep hepatitis B suppressed
This Phase 2 trial studies an injection (HRS-5635), either alone or with other medicines, to see if it is safe and helps keep chronic hepatitis B under control. It is for people who are already on standard hepatitis B antivirals and have low or undetectable viral levels.
Guangzhou, GuangdongAges 18 years+ - NCT06435429RecruitingPhase 3
Zanidatamab vs trastuzumab for HER2+ breast cancer
This study compares a new drug called zanidatamab against trastuzumab (Herceptin), both given with a chemotherapy of your doctor's choice. It is for people with HER2-positive breast cancer that has spread and who have already tried T-DXd treatment.
Phoenix, ArizonaAges 18 years+ - NCT06431893Enrolling by invitationPhase 3
Long-term study of pegtibatinase for classical homocystinuria
This trial is a long-term follow-up study examining the safety and effectiveness of pegtibatinase for people with classical homocystinuria (HCU). It is open to those who have recently taken part in or finished the HARMONY or COMPOSE studies.
Phoenix, ArizonaAges 5–65 - NCT06423235RecruitingPhase 4
Prunella oral liquid for thyroid nodules
This trial tests if an herbal liquid made from prunella can shrink benign thyroid nodules. It may be an option for people with solid, non-cancerous nodules who want to avoid surgery.
Chongqing, Chongqing MunicipalityAges 18–65
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.